Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
13F holders, Q3 2024 (September 30)9holders −2
1new positions
2sold out
$2.08avg. 13F price*
At the end of Q3 2024, 9 institutions reported holding Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) in their 13F filings, down 2 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Nomura Holdings Inc. ($19.8M), Lord, Abbett & Co. LLC ($12.4M) and New York State Common Retirement Fund ($5.1M).
- Company
- Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
- CUSIP
- 803607AD2
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $6K |
| Exits | 2 | $5.6M |
All 13F filers, Q2 2024 → Q3 2024: 605,500 shares bought and 3,257,665 shares sold, net −2,652,165 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Nomura Holdings Inc. | 0.15% | No change | 158,890 | $19.8M |
| Lord, Abbett & Co. LLC | 0.04% | Reduce -1.7% | 10,892,000 | $12.4M |
| New York State Common Retirement Fund | 0.01% | Add +15.3% | 4,497,000 | $5.1M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | Reduce -9.3% | 4,400,000 | $5.0M |
| Bank of New York Mellon Corp | 0.00% | Reduce -11.1% | 800,000 | $910K |
| Choreo, LLC | 0.00% | Add +13.3% | 17,000 | $19K |
| Stonegate Investment Group, LLC | 0.00% | No change | 13,000 | $15K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | New | 5,500 | $6K |
| Rothschild Investment LLC | 0.00% | No change | 1,000 | $1K |
"% of holder's portfolio" is SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27)'s weight in each manager's 13F, not the share of Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) the manager owns.